Treatment with nilotinib is associated with improvements in quality of life for patients with chronic myeloid leukemia in chronic phase (CML-CP) receiving second-line therapy, a study published in the journal Clinical Lymphoma, Myeloma & Leukemia has shown.1
To evaluate quality of life and adherence to therapy in patients with CML-CP treated with second-line nilotinib, researchers enrolled 177 patients from 23 centers in Poland receiving nilotinib after first-experiencing disease progression or unacceptable toxicity while on their previous therapy.
Researchers assessed quality of life using the standard Core Quality of Life (EORTC QLQ-C30) questionnaire and measured adherence to therapy with the use of the 4-item Morisky Medication Adherence Scale (MMAS) by patients and their physicians.
Results showed that the average quality of life of patients who completed the study was significantly higher during the last visit compared with that at the time of enrollment (P <.001).
Investigators also found that 83.2% of patients perceived themselves as highly compliant to nilotinib therapy at their first visit, with 93.4% rating themselves as highly compliant at the fifth visit. Only 1.7% of patients were considered to have low compliance at the first visit and no patients assessed themselves as low compliant since the fourth visit, suggesting high adherence.
According to physicians, 85.3% of patients were highly compliant at the first visit and 96.0% were categorized the same during the last 3 visits.
The findings ultimately suggest that second-line treatment with nilotinib can significantly improve quality of life in patients with CML-CP and adherence to therapy is high.
1. Sacha T, Gora-Tybor J, Wasak-Szulkowska E, et al. Quality of life and adherence to therapy in patients with chronic myeloid leukemia treated with nilotinib as a second line therapy: a multicenter prospective observational study. Clin Lymphoma Myeloma Leuk. 2017 Jan 10. doi: 10.1016/j.clml.2017.01.001. [Epub ahead of print]